Case Study

Side Effects of Inhaled Glucocorticoids for Asthma Treatment

Metabolon helps researchers understand how the dosage of glucocorticoids (GCs) impacts side effects experienced by patients with asthma.

Talk With An Expert About Your Project

Side Effects of Inhaled Glucocorticoids for Asthma Treatment

The Challenge: Current Asthma Treatment Has Chronic Side Effects

Asthma is one of the most prevalent noncommunicable diseases attacking both adults and children. According to the World Health Organization (WHO), an estimated 262 million people were affected by the disease in 2019, while 45,000 died from asthma attacks.¹ In the U.S., about 25 million people suffer from asthma, which is equivalent to 1 person for every 13 U.S. residents.²

Some methods of controlling the disease include anti-inflammatory inhaled glucocorticoids (GCs) and smooth muscle-relaxing bronchodilators. Although GCs have been used as the standard care for asthma, inhaled GCs can affect adrenal storage pathways. Chronic use of high-dose inhaled GCs can cause systemic adverse effects such as hypothalamus-pituitary-adrenal (HPA) axis dysfunction, hyperglycemia, skin thinning, bruising, and perturbed energy metabolism.

While GC effects have been studied using the HPA axis or specific organ systems, not much has been done to classify GC effects at a molecular level, and the differences between GC molecules have not been determined.³ A study was conducted to understand how the dosage of glucocorticoids (GCs) impacts side effects experienced by patients. This study sought to determine the systemic effects of inhaled GCs at a molecular level using metabolomics.

The team evaluated the effects of 3 inhaled GC molecules—fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD)—in randomized, escalating-dose, placebo-controlled, incomplete-block study in patients with mild asthma.

Patients were randomly selected and given 1 or 2 of the 4 treatments (FF, FP, BUD, or placebo) with a washout period of 25 to 42 days. Each of the 4 treatment periods lasted 35 days with 5 successive dose escalations lasting 7 days. Plasma samples were analyzed using the Metabolon Global Discovery Panel.

Metabolon Insight: Metabolomics Reveals Pathways Impacted by Glucocorticoids

Small molecule metabolites play a vital role in understanding biological systems and represent an effective and modern approach to understanding the phenotype of diseases such as asthma, but their low molecular weight structure makes analysis a challenging assignment to accomplish.

The Global Discovery Panel enables the separation, detection, characterization, and relative quantification of such metabolites using our proprietary software and unmatched chemical library of more than 5400 metabolites. Following a rigorous quality control process, such a high-precision dataset provides a comprehensive perspective of the underlying biology which can be interpreted by our expert biochemists to provide powerful, actionable insights.

The Solution: Comprehensive Metabolomics Analysis of Glucocorticoid Effects

Results from the study showed that inhaled GCs induce significant changes in several biochemical pathways only at high and supratherapeutic doses, thus supporting the safety of low- and mid-therapeutic doses. These changes include a reduction in metabolites related to adrenal steroids, anti-inflammatory mediators and precursors, and tricarboxylic acid (TCA) cycle intermediates.

As a means to inform precision medicine approaches, metabolomics analysis made it possible to compare different GC types and dosages, thus potentially guiding future therapy decisions for patients who are sensitive to adrenal disruption.

The Outcome: Precision Medicine in Asthma Treatment

Results from this study illustrate how metabolomics can be employed to elucidate the systemic effects of different asthma medications at the molecular level since metabolites directly reveal the underlying biology of cells.

References

1. Asthma. World Health Organization. Published 2022 May 11. Available at: https://www.who.int/news-room/fact-sheets/detail/asthma

2. Daley-Yates, P., Keppler, B., Brealey, N., Shabbir, S., Singh, D., & Barnes, N. Inhaled glucocorticoid-induced metabolome changes in asthma, European Journal of Endocrinology, 187(3), 413-427. Published 2022 July 29. Available at: https://doi.org/10.1530/EJE-21-0912

3. Clary B. Clish. Metabolomics: an emerging but powerful tool for precision medicine. Cold Spring Harbor Mol Case Stud. 2015 Oct; 1(1): a000588. Published 2016 Jan 1. doi:10.1101/mcs.a000588

Related Case Studies

See All Case Studies

Metabolomics finds PanK4 to be an Important Regulator of Glucose Uptake and Lipid Metabolism

Find out more $

Metabolomics provides insight into the pathology of sudden infant death syndrome and identifies biomarker candidates

Find out more $

Metabolomics Reveals Beneficial Changes to Metabolite Profiles During Diabetes Remission

Find out more $

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.